Baidu
map

JAMA Neurol:进展性多发性硬化患者炎症与残疾的关系

2018-08-09 zhangfan MedSci原创

累进性多发性硬化症患者,重叠复发与确诊残疾进展风险降低相关,疾病修正疗法在预防复发性相关残疾的过程中发挥了关键作用

炎症性疾病活动是进展性多发性硬化症(MS)残疾程度恶化的重要因素,近日研究人员就进展性多发性硬化患者多次复发与疾病预后的关系进行了考察。

1419名初次进展性复发的MS患者(PPMS)或进展性复发MS患者(PRMS)参与研究,根据是否有再次复发分组,多次复发患者定义为急性发作临床恶化。研究的主要终点为累积的致残性进展风险。

PRMS患者年龄较低(46 vs 51岁),病情扩展残疾情况评分也较低(4.0 vs 4.5)。组间男女患者比例相近,男性患者平均年龄48岁,女性患者平均年龄50岁。研究发现复发性患者确诊的残疾进展可能性较低(HR=0.83)。病性改善疗法可显著减少复发患者残疾进展风险(HR=0.96),但对于非复发患者效果不显著(HR=1.02)。在考虑复发相关进展时,多次复发患者接受病性改善疗法的收益消失(HR=1.10)。

累进性多发性硬化症患者,重叠复发与确诊残疾进展风险降低相关,疾病修正疗法在预防复发性相关残疾的过程中发挥了关键作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000533, encodeId=16a0200053329, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 28 11:32:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889935, encodeId=4d8c1889935a1, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed May 15 01:32:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337474, encodeId=8a8c33e4742b, content=谢谢分享,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Aug 09 07:44:19 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2019-04-28 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000533, encodeId=16a0200053329, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 28 11:32:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889935, encodeId=4d8c1889935a1, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed May 15 01:32:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337474, encodeId=8a8c33e4742b, content=谢谢分享,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Aug 09 07:44:19 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2019-05-15 jml2009
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000533, encodeId=16a0200053329, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Apr 28 11:32:00 CST 2019, time=2019-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889935, encodeId=4d8c1889935a1, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed May 15 01:32:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337474, encodeId=8a8c33e4742b, content=谢谢分享,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Aug 09 07:44:19 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-09 phoebeyan520

    谢谢分享,谢谢分享

    0

Baidu
map
Baidu
map
Baidu
map